BI-2536   Click here for help

GtoPdb Ligand ID: 5666

Synonyms: BI 2536 | BI2536
PDB Ligand
Compound class: Synthetic organic
Comment: BI-2536 was initially reported as a polo-like kinase 1 (PLK1) inhibitor [3]. More recently, this compound has been discovered to function, in addition, as a BRD4 (bromodomain) inhibitor [1]. It is suggested that BI-2536 be termed a dual kinase-bromodomain inhibitor.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 102.93
Molecular weight 521.31
XLogP 3.44
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CCC1N(C2CCCC2)c2nc(ncc2N(C1=O)C)Nc1ccc(cc1OC)C(=O)NC1CCN(CC1)C
Isomeric SMILES CC[C@H]1N(C2CCCC2)c2nc(ncc2N(C1=O)C)Nc1ccc(cc1OC)C(=O)NC1CCN(CC1)C
InChI InChI=1S/C28H39N7O3/c1-5-22-27(37)34(3)23-17-29-28(32-25(23)35(22)20-8-6-7-9-20)31-21-11-10-18(16-24(21)38-4)26(36)30-19-12-14-33(2)15-13-19/h10-11,16-17,19-20,22H,5-9,12-15H2,1-4H3,(H,30,36)(H,29,31,32)/t22-/m1/s1
No information available.
Summary of Clinical Use Click here for help
Several Phase 2 clinical trials assessing BI-2536 have been completed. Indications included non-small-cell lung cancer (NSCLC), relapsed/refactory acute myeloid leukemia (AML) and prostate, breast, endometrial and head and neck cancers. Click here to view a complete listing of Phase 2 BI-2536 trials registered with